Inhaled nitric oxide as rescue therapy in severe ARDS cases due to COVID-19 pneumonia: a single center experience

Basit Öğe Kaydı
dc.authoridbicakcioglu, murat/0000-0001-9101-6857
dc.authorwosidbicakcioglu, murat/AAA-8149-2022
dc.contributor.authorBicakcioglu, M.
dc.contributor.authorKalkan, S.
dc.contributor.authorDuzenci, D.
dc.contributor.authorYalcinsoy, M.
dc.contributor.authorDogan, Z.
dc.contributor.authorOzer, A. B.
dc.date.accessioned2024-08-04T20:54:31Z
dc.date.available2024-08-04T20:54:31Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractOBJECTIVE: Inhaled NO (iNO) has been recommended as rescue therapy in acute respiratory stress syndrome (ARDS) cas-es. In this study, we aimed to demonstrate the efficacy of iNO as a rescue therapy in patients with severe ARDS due to COVID-19.PATIENTS AND METHODS: This retrospec-tive study included patients with ARDS due to COVID-19 who were treated with iNO between March 2020 and January 2022 in the intensive care unit (ICU) of Inonu University. Patients' files were reviewed retrospectively, and de-mographic data, APACHE II and Sequential Or-gan Failure Assessment (SOFA) scores, initia-tion day of iNO and duration of iNO treatment, length of stay in hospital/ICU, blood biochem-istry values, complete blood counts, inflamma-tory parameters, arterial blood gas values, lac-tate, PaO2/FiO2 ratios, anti-inflammatory drugs and outcome were recorded.RESULTS: Data from 16 patients were reached. iNO was given at a dose of 20 ppm continuously. The mean duration of treatment with iNO was 3.5 days. All patients took the prone position except a single patient. While all patients received steroid therapy, four pa-tients received anti-cytokine therapy, and five patients received intravenous immunoglobulin therapy. All patients were in severe ARDS with a mean PaO2/FiO2 ratio of 58 before iNO ther-apy. A significant increase in PaO2/FiO2 val-ues was detected with the use of iNO (p<0.05). While three patients (19%) were discharged from the ICU, thirteen patients died.CONCLUSIONS: In our study, it was deter-mined that iNO applied as a rescue treatment in patients with severe ARDS improved oxygen-ation. Although the effect of iNO on survival was low, it may be interpreted as clinically signifi-cant considering the severity of the general clin-ical condition of the patients.en_US
dc.identifier.endpage6428en_US
dc.identifier.issn1128-3602
dc.identifier.issue13en_US
dc.identifier.pmid37458665en_US
dc.identifier.scopus2-s2.0-85165063712en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage6422en_US
dc.identifier.urihttps://hdl.handle.net/11616/101472
dc.identifier.volume27en_US
dc.identifier.wosWOS:001045159300017en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcute respiratory distress syndromeen_US
dc.subjectInhaled nitric oxideen_US
dc.subjectCOVID-19en_US
dc.subjectIntensive careen_US
dc.subjectMortalityen_US
dc.titleInhaled nitric oxide as rescue therapy in severe ARDS cases due to COVID-19 pneumonia: a single center experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu